InflaRx N.V. (IFRX) vs SIGA Technologies (SIGA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
InflaRx N.V. (IFRX) has outperformed SIGA Technologies (SIGA) over the past year, gaining 4.1% versus a loss of 60.4%. Over five years, IFRX leads with a -38.1% price change compared with -53.9% for SIGA. SIGA Technologies is the larger company by market cap ($235.7 million vs $225.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IFRX | SIGA |
|---|---|---|
| Share price | $1.53 | $3.28 |
| Market cap | $225.47M | $235.67M |
| 1-day change | -1.92% | +0.61% |
| YTD return | +51.49% | -46.32% |
| 1-year return | +4.08% | -60.39% |
| 5-year return | -38.06% | -53.87% |
| Forward P/E | — | 3.04 |
| EPS (TTM) | $-0.58 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.95 | $8.55 |
| 52-week low | $0.798 | $2.83 |
| Distance from 52-week high | -48.12% | -61.64% |
| Analyst consensus | none | none |
| Avg. price target upside | +400.65% | — |
| Average volume | 794.10K | 726.50K |
| Shares outstanding | 147.37M | 71.85M |
| Employees | 65 | 49 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IFRX has outperformed SIGA by 64.5 percentage points over the past year.
- The two companies sit in different sectors: InflaRx N.V. in Healthcare and SIGA Technologies in Health Care.
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Healthcare · Biotechnology · 65 employees
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
IFRX vs SIGA FAQ
Which is bigger, InflaRx N.V. or SIGA Technologies?
SIGA Technologies (SIGA) is larger, with a market capitalization of $235.67M compared with $225.47M for InflaRx N.V. (IFRX).
Which stock has performed better over the past year, IFRX or SIGA?
IFRX returned +4.08% over the past 12 months, compared with -60.39% for SIGA (price return, excluding dividends). Past performance does not predict future results.
Are InflaRx N.V. and SIGA Technologies in the same industry?
No. InflaRx N.V. is in the Healthcare sector, while SIGA Technologies is in Health Care.